Entropy Technologies LP Sells 14,196 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Entropy Technologies LP lessened its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 55.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,493 shares of the company’s stock after selling 14,196 shares during the period. Entropy Technologies LP’s holdings in Replimune Group were worth $126,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Quest Partners LLC increased its holdings in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Algert Global LLC grew its stake in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after acquiring an additional 4,340 shares in the last quarter. Creative Planning raised its holdings in shares of Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on REPL. JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Tuesday, November 12th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and a consensus price target of $16.80.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $10.80 on Monday. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. The stock has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $9.57. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $12.97. The firm has a market cap of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Analysts anticipate that Replimune Group, Inc. will post -3.02 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.